Evidence map›Paper›PMID 24862029›Full record

Trial reportJAMA neurology2014

Insights from cerebellar transcriptomic analysis into the pathogenesis of ataxia.

Conceição Bettencourt, Mina Ryten, Paola Forabosco, Stephanie Schorge, Joshua Hersheson, John Hardy, Henry Houlden, United Kingdom Brain Expression Consortium

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in JAMA neurology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed.

  1. Article
  2. Detailed Analysis of ITPR1 Missense Variants Guides Diagnostics and Therapeutic Design.Movement disorders : official journal of the Movement Disorder Society · 2024
    Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. From Mice to Men: TRPC3 in Cerebellar Ataxia.Cerebellum (London, England) · 2017
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Conceição BettencourtDepartment of Molecular Neuroscience, UCL Institute of Neurology, London, England.
Mina RytenDepartment of Molecular Neuroscience, UCL Institute of Neurology, London, England2Department of Medical and Molecular Genetics, King's College London, London, England.
Paola ForaboscoIstituto di Ricerca Genetica e Biomedica, Consiglio Nazionale delle Ricerche, Cagliari, Italy.
Stephanie SchorgeDepartment of Clinical and Experimental Epilepsy, UCL Institute of Neurology, London, England.
Joshua HershesonDepartment of Molecular Neuroscience, UCL Institute of Neurology, London, England.
John HardyDepartment of Molecular Neuroscience, UCL Institute of Neurology, London, England.
Henry HouldenDepartment of Molecular Neuroscience, UCL Institute of Neurology, London, England.
United Kingdom Brain Expression Consortium

Funding

Medical Research Council G0601440Medical Research Council G0802462Medical Research Council G0802760Medical Research Council G0901254Medical Research Council G1001253Medical Research Council G108/638Medical Research Council MC_G1000735Medical Research Council MR/J004758/1Medical Research Council MR/K000608/1Medical Research Council MR/K01417X/1Medical Research Council WT089698Wellcome Trust 089698
6 · The paper itself

Abstract

importanceThe core clinical and neuropathological feature of the autosomal dominant spinocerebellar ataxias (SCAs) is cerebellar degeneration. Mutations in the known genes explain only 50% to 60% of SCA cases. To date, no effective treatments exist, and the knowledge of drug-treatable molecular pathways is limited. The examination of overlapping mechanisms and the interpretation of how ataxia genes interact will be important in the discovery of potential disease-modifying agents.

objectivesTo address the possible relationships among known SCA genes, predict their functions, identify overlapping pathways, and provide a framework for candidate gene discovery using whole-transcriptome expression data. DESIGN, SETTING, AND

participantsWe have used a systems biology approach based on whole-transcriptome gene expression analysis. As part of the United Kingdom Brain Expression Consortium, we analyzed the expression profile of 788 brain samples obtained from 101 neuropathologically healthy individuals (10 distinct brain regions each). Weighted gene coexpression network analysis was used to cluster 24 SCA genes into gene coexpression modules in an unsupervised manner. The overrepresentation of SCA transcripts in modules identified in the cerebellum was assessed. Enrichment analysis was performed to infer the functions and molecular pathways of genes in biologically relevant modules. MAIN OUTCOMES AND MEASURES: Molecular functions and mechanisms implicating SCA genes, as well as lists of relevant coexpressed genes as potential candidates for novel SCA causative or modifier genes.

resultsTwo cerebellar gene coexpression modules were statistically enriched in SCA transcripts (P = .021 for the tan module and P = 2.87 × 10-5 for the light yellow module) and contained established granule and Purkinje cell markers, respectively. One module includes genes involved in the ubiquitin-proteasome system and contains SCA genes usually associated with a complex phenotype, while the other module encloses many genes important for calcium homeostasis and signaling and contains SCA genes associated mostly with pure ataxia. CONCLUSIONS AND RELEVANCE: Using normal gene expression in the human brain, we identified significant cell types and pathways in SCA pathogenesis. The overrepresentation of genes involved in calcium homeostasis and signaling may indicate an important target for therapy in the future. Furthermore, the gene networks provide new candidate genes for ataxias or novel genes that may be critical for cerebellar function.

Indexed as

Tissue BanksCerebellar DiseasesGene Expression ProfilingGene Expression RegulationGenetic LociHumansMutationSpinocerebellar Ataxias

Identifiers

PMID24862029
PMCPMC4469030

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.